Lupus & antiphospholipid syndrome
Adherence to antimalarials and glucocorticoids treatment and its association with self-reported disease activity in systemic lupus erythematosus patients
Authors' conclusion
Adherence to the treatment indicated in SLE differs from drug to drug.
Study context
- Population
- Cohort of Systemic lupus erythematosus (SLE) patients
- Participants
- 670 participants
- Exposure
- Non-adherence vs adherence to antimalarials and glucocorticoids (GCs)
- Outcome
- Rate of non-adherence to antimalarials and GCs
Main finding
As reported in the abstract
Prevalence of non-adherence
Non-adherence to antimalarials
10.67%
Non-adherence to GCs
39.61%
Observational data: associations, not effects.
Further findings
| Outcome | Non-adherence | Adherence | P value |
|---|---|---|---|
| Disease severity (SLAQ), non-adherence vs adherence to antimalarialsSignificantly higher scores with non-adherence | 5.03 | 4.39 | P = 0.004 |
| Disease severity (SLAQ), non-adherence vs adherence to GCsSignificantly higher scores with non-adherence | 4.75 | 4.05 | P ≤ 0.001 |
- Disease severity (SLAQ), non-adherence vs adherence to antimalarials: values printed as 5.03 (2.12) vs 4.39 (2.61); spread kind not stated
- Disease severity (SLAQ), non-adherence vs adherence to GCs: values printed as 4.75 (2.29) vs 4.05 (2.78); spread kind not stated
Reason for stopping therapy
- Presence of side effects
- 86.9%
Original publication
Adherence to antimalarials and glucocorticoids treatment and its association with self-reported disease activity in systemic lupus erythematosus patients. Lupus. Published 8 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →